Browse > Article
http://dx.doi.org/10.7314/APJCP.2015.16.4.1545

Carcinoma Microsatellite Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Stage II Rectal Cancer  

Yang, Liu (Colorectal Cancer Center, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Sun, Yan (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Huang, Xin-En (Department of Chemotherapy, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Yu, Dong-Sheng (Colorectal Cancer Center, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Zhou, Jian-Nong (Colorectal Cancer Center, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Zhou, Xin (Colorectal Cancer Center, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Li, Dong-Zheng (Colorectal Cancer Center, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Guan, Xin (Colorectal Cancer Center, the Affiliated Jiangsu Cancer Hospital of Nanjing Medical University & Jiangsu Institute of Cancer Research)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.16, no.4, 2015 , pp. 1545-1551 More about this Journal
Abstract
Purpose: Rectal cancers with high microsatellite-instable have clinical and pathological features that differentiate them from microsatellite-stable or low-frequency carcinomas, which was studied rarely in stage II rectal cancer, promoting the present investigation of the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II rectal cancer. Patients and Methods: Data of 460 patients who underwent primary anterior resection with a double stapling technique for rectal carcinoma at a single institution from 2008 to 2012 were retrospectively collected. All patients experienced a total mesorectal excision (TME) operation. Survival analysis were analyzed using the Cox regression method. Results: Five-year rate of disease-free survival (DFS) was noted in 390 (84.8%) of 460 patients with stage II rectal cancer. Of 460 tissue specimens, 97 (21.1%) exhibited high-frequency microsatellite instability. Median age of the patients was 65 (50-71) and 185 (40.2%) were male. After univariate and multivariate analysis, microsatellite instability (p= 0.001), female sex (p<0.05) and fluorouracil-based adjuvant chemotherapy (p<0.001), the 3 factors were attributed to a favorable survival status independently. Among 201 patients who did not receive adjuvant chemotherapy, those cancers displaying high-frequency microsatellite instability had a better 5-year rate of DFS than tumors exhibiting microsatellite stability or low-frequency instability (HR, 13.61 [95% CI, 1.88 to 99.28]; p= 0.010), while in 259 patients who received adjuvant chemotherapy, there was no DFS difference between the two groups (p= 0.145). Furthermore, patients exhibiting microsatellite stability or low-frequency instability who received adjuvant chemotherapy had a better 5-year rate of DFS than patients did not (HR, 5.16 [95% CI, 2.90 to 9.18]; p<0.001), while patients exhibiting high-frequency microsatellite instability were not connected with increased DFS (p= 0.696). It was implied that female patients had better survival than male. Conclusion: Survival status after anterior resection of rectal carcinoma is related to the microsatellite instability status, adjuvant chemotherapy and gender. Fluorouracil-based adjuvant chemotherapy benefits patients of stage II rectal cancer with microsatellite-stable or low microsatellite-instable, but not those with high microsatellite-instable. Additionally, free of adjuvant chemotherapy, carcinomas with high microsatellite-instable have a better 5-year rate of DFS than those with microsatellite-stable or low microsatellite-instable, and female patients have a better survival as well.
Keywords
Rectal cancer; microsatellite instability; survival analysis; adjuvant chemotherapy;
Citations & Related Records
Times Cited By KSCI : 5  (Citation Analysis)
연도 인용수 순위
1 Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis (2008). Gastroenterology, 135, 1079-99.   DOI
2 Gryfe R, Kim H, Hsieh ETK, et al (2000). Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med, 342, 69-77.   DOI
3 Halling KC, French AJ, McDonnell SK, et al (1999). Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst, 91, 1295-303.   DOI
4 Hemminki A, Mecklin JP, Jarvinen H, et al (2000). Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology, 119, 921-8.   DOI
5 Inamura K, Yamauchi M, Nishihara R, et al (2014). Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer prognosis. J Natl Cancer Inst, 106, dju195.
6 Kim H, Jen J, Vogelstein B, et al (1994). Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol, 145, 148-56.
7 Kuismanen SA, Holmberg MT, Salovaara R, et al (2000). Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol, 156, 1773-9.   DOI
8 Lanza G, Gafa R, Santini A, et al (2006). Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol, 24, 2359-67.   DOI
9 Lengauer C, Kinzler KW, Vogelstein B (1997). Genetic instability in colorectal cancers. Nature, 386, 623-7.   DOI
10 Lynch HT, Lynch PM, Lanspa SJ, et al (2009). Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet, 76, 1-18.
11 Midgley R, Kerr DJ (2005). Adjuvant chemotherapy for stage II colorectal cancer: the time is right! Nat Clin Pract Oncol, 2, 364-9.   DOI
12 Popat S, Hubner R, Houlston RS (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol, 23, 609-18.   DOI
13 Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatelliteinstability status as a predictor of benefit from fluorouracilbased adjuvant chemotherapy for colon cancer (2003). N Engl J Med, 349, 247-57.   DOI
14 Rudolph A, Toth C, Hoffmeister M, et al (2012). Expression of oestrogen receptor ${\beta}$ and prognosis of colorectal cancer. Br J Cancer, 107, 831-9.   DOI   ScienceOn
15 Thibodeau SN, Bren G, Schaid D (1993). Microsatellite instability in cancer of the proximal colon. Science, 260, 816-9.   DOI
16 Oduwole OO, Makinen MJ, Isomaa VV, et al (2003). 17Beta-hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer. J Steroid Biochem Mol Biol, 87, 133-40.   DOI
17 Tjandra JJ, Kilkenny JW, Buie WD, et al (2005). Standards practice task force; American society of colon and rectal surgeons. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum, 48, 411-23.   DOI
18 Whitehall V, Dumenil T, McKeone D, et al (2014). Isocitrate dehydrogenase 1 R132C mutation occurs exclusively in microsatellite stable colorectal cancers with the CpG island methylator phenotype. Epigenetics, 9, 1454-60.   DOI
19 Ahmedin J, Freddie B, Melissa MC, et al (2011). Global cancer statistics. Ca Cancer J Clin, 61, 69-90.   DOI
20 Wright CM, Dent OF, Barker M, et al (2000). Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg, 87, 1197-202.   DOI
21 Yang L, Huang XE, Zhou JN (2013). Risk assessment on AL after rectal cancer surgery: an analysis of 753 patients. Asian Pac J Cancer Prev, 14, 4447-53.   DOI   ScienceOn
22 Yang L, Huang XE, Xu L, et al (2013). Acidic pelvic drainage as a predictive factor for AL after surgery for patients with rectal cancer. Asian Pac J Cancer Prev, 14, 5441-7.   DOI   ScienceOn
23 Ahn JB, Chung WB, Maeda O, et al (2011). DNA methylation predicts recurrence from resected stage III proximal colon cancer. Cancer, 117, 1847-54.   DOI
24 Andre T, Boni C, Navarro M, et al (2009). Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 27, 3109-16.   DOI
25 Bertagnolli MM, Niedzwiecki D, Compton CC, et al (2009). Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol, 27, 1814-21.   DOI
26 Chen YS, Xu SX, Ding YB, et al (2013). Helicobacter pylori Infection and the risk of colorectal adenoma and adenocarcinoma: an updated meta-analysis of different testing methods. Asian Pac J Cancer Prev, 14, 7613-9.   DOI   ScienceOn
27 Chen YS, Xu SX, Ding YB, et al (2014). Colorectal cancer screening in high-risk populations: a survey of cognition among medical professionals in Jiangsu, China. Asian Pac J Cancer Prev, 14, 6487-91.
28 Cunningham MJ, Christensen ER, Tester DJ, et al (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res, 58, 3455-60.
29 Des Guetz G, Schischmanoff O, Nicolas P, et al (2009). Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer, 45, 1890-6.   DOI
30 Gong JP, Yang L, Huang XE, et al (2014). Outcomes based on risk assessment of anastomotic leakage after rectal cancer surgery. Asian Pac J Caner Prev, 15, 707-12.   DOI   ScienceOn